Real-WorlD ZolbetUximab in Patients With HER-2 Negative and CLaudin 18.2 PosItive MetastatiC AdEnocarcinoma

The primary objective is to validate, throughout a national real-world study, the efficacy and safety of Zolbetuximab combined with FOLFOX or XELOX regimens. Specific clinical issues will be studied by pre-planned subgroup analyses, addressing practical clinical needs which have not been specifically investigated in randomized clinical trials.

NCT Number	NCT07427992
Lead Sponsor	European Institute of Oncology
Conditions	Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Enrollment	70 participants
Start Date	2025-06-20
Primary Completion	2026-12-30 (estimated)
Study Completion	2027-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-02-23